Sugi Predict

Sugi Predict / Compounds / SCHEMBL19693589

SCHEMBL19693589

SCHEMBL19693589

CC(C)c1ncncc1-c1cc(F)ccc1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 2/20 0.44
▸ CYP17A1 P05093 1/20 0.40
▸ CYP11B1 P15538 1/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ CYP3A4 P08684 7/20 0.38
▸ GCGR P47871 3/20 0.37
▸ CYP2C19 P33261 2/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2B6 P20813 1/20 0.36
▸ CYP3A5 P20815 1/20 0.36
▸ CYP3A7 P24462 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP3A43 Q9HB55 1/20 0.36
▸ CYP46A1 Q9Y6A2 1/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TOP2A P11388 1/20 0.36
▸ EIF4E P06730 1/20 0.35
▸ HSP90AA1 P07900 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29519877 1.00 IDO1 (0.44) IDO1CYP17A1CYP11B1CYP11B2NPC1
SCHEMBL31319263 0.73 IDO1 (0.46) IDO1NPC1CYP3A4CYP2C19TOP2A
SCHEMBL23529616 0.72 CYP17A1 (0.48) IDO1CYP17A1CYP11B1CYP11B2NPC1
SCHEMBL8059885 0.71 IDO1 (0.57) IDO1NPC1CYP3A4CYP2C19CYP2C9
SCHEMBL2611027 0.69 GABRA1 (0.33) CYP17A1CYP11B1CYP11B2
SCHEMBL25599467 0.68 IDO1 (0.39) IDO1NPC1TOP2AALDH1A1
SCHEMBL20466856 0.66 NCOA1 (0.42) CYP17A1CYP3A4GCGRCYP2C19MAPK1
SCHEMBL25522049 0.66 SLC22A12 (0.38) CYP17A1CYP11B1CYP11B2CYP3A4GCGR
SCHEMBL31349669 0.66 NPC1 (0.48) IDO1NPC1CYP3A4MAPK1LMNA
SCHEMBL31549500 0.66 NPC1 (0.48) IDO1NPC1CYP3A4MAPK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2025-10-23 — — US disclosed
US-12312359-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2025-05-27 — — US disclosed
WO-2023125928-A1 MENIN INHIBITOR AND USE THEREOF 成都先导药物开发股份有限公司 2023-07-06 — — WO disclosed
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2023-06-08 — — US disclosed
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2023-06-08 — — US disclosed
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2023-06-08 — — US disclosed
US-11479557-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2022-10-25 — — US disclosed
US-11479557-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2022-10-25 — — US disclosed
CN-109743875-B Inhibitors of the MENIN-MLL interaction 生命医药有限责任公司 2022-04-29 — — CN disclosed
EP-3805215-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Vitae Pharmaceuticals, LLC (US) 2021-04-14 — — EP disclosed
US-20210053974-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC (US) 2021-02-25 — — US disclosed
EP-3468966-B1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2020-08-05 — — EP disclosed
EP-3468966-B1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS LLC (US) 2020-08-05 — — EP disclosed
US-10683302-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2020-06-16 — — US disclosed
US-10683302-B2 Inhibitors of the menin-MLL interaction VITAE PHARMACEUTICALS, LLC (US) 2020-06-16 — — US disclosed
US-20190144459-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2019-05-16 — — US disclosed
US-20190144459-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, LLC 2019-05-16 — — US disclosed
EP-3468966-A1 INHIBITORS OF THE MENIN-MLL INTERACTION Vitae Pharmaceuticals, Inc. (US) 2019-04-17 — — EP disclosed
WO-2017214367-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, INC. (US) 2017-12-14 — — WO disclosed
WO-2017214367-A1 INHIBITORS OF THE MENIN-MLL INTERACTION VITAE PHARMACEUTICALS, INC. (US) 2017-12-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230174541-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-12312359-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-20190144459-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-11479557-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-10683302-B2 Inhibitors of the menin-MLL interaction MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-20210053974-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885
US-20250326764-A1 INHIBITORS OF THE MENIN-MLL INTERACTION MLLT1, MEN1, MLLT3 IDO1 3582/4885CYP17A1 3556/4885CYP11B1 2917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.